Sign In
Buy HIMS
$27.51
+0 (+0%)
At Close: Jun 03, 2026
Hims & Hers Health: Another Blowout Quarter Ignored
11:00am, Tuesday, 05'th Nov 2024
Hims & Hers Health, Inc. reported record Q3 '24 revenues of over $400 million, beating estimates by nearly $19 million, and guided for up to 90% growth in Q4. The online health and wellness platform s
HIMS Stock Gains Following In Line Q3 Earnings, Gross Margin Contracts
10:56am, Tuesday, 05'th Nov 2024
Hims & Hers' both revenue channels witness strong revenue growth on the back of solid product demand in the third quarter.
Hims & Hers Stock Jumps. A Generic Version of Novo Nordisk Diabetes Drug Is Close.
08:30am, Tuesday, 05'th Nov 2024
The telehealth company will launch a generic version of Novo's type 2 diabetes drug liraglutide in 2025.
Hims & Hers: A Lot More Than Just GLP-1, And It's Proving Its Ability To Grow
10:30pm, Monday, 04'th Nov 2024
Hims & Hers' strong Q3 results and 77% y/y revenue growth demonstrate its robust business, justifying a continued strong buy rating despite FDA uncertainties. Shares rallied ~5% in after-hours trading
Hims & Hers Health, Inc. (HIMS) Q3 2024 Earnings Call Transcript
08:58pm, Monday, 04'th Nov 2024
Hims & Hers Health, Inc. (NYSE:HIMS ) Q3 2024 Earnings Conference Call November 4, 2024 5:00 PM ET Company Participants Bill Newby - Head, IR Andrew Dudum - Co-Founder and CEO Yemi Okupe - CFO Patrick
Markets Temper Enthusiasm Ahead of Election Day
07:15pm, Monday, 04'th Nov 2024
We don't expect any sudden movements in the stock market until Wednesday morning the earliest.
Hims & Hers Health, Inc. (HIMS) Q3 Earnings Match Estimates
06:46pm, Monday, 04'th Nov 2024
Hims & Hers Health, Inc. (HIMS) came out with quarterly earnings of $0.06 per share, in line with the Zacks Consensus Estimate. This compares to loss of $0.04 per share a year ago.
Hims & Hers shares rally on results, but execs say GLP-1 drug shortage ‘is not abating'
06:28pm, Monday, 04'th Nov 2024
Shares of Hims & Hers Health Inc. rallied after hours on Monday after the wellness platform bumped its full-year sales forecast higher, as its efforts to offer more personalized care and more weight-l
Hims & Hers Health plans to offer generic version of Novo Nordisk's diabetes drug in 2025
06:10pm, Monday, 04'th Nov 2024
Telehealth firm Hims & Hers Health said on Monday it plans to bring a generic version of Novo Nordisk's diabetes drug, liraglutide, to its platform in 2025.
HIMS Q3 Estimates Unchanged Before Earnings: How to Play the Stock?
12:15pm, Friday, 01'st Nov 2024
The continued solid uptake of Hims & Hers offerings and expanding subscriber base are likely to have driven the company's performance in the third quarter.
Could This Magnificent Pharma Stock 10x in the Next 5 Years?
07:30am, Wednesday, 30'th Oct 2024
Disrupting pharmacies is just the start for Hims & Hers.
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
10:05am, Tuesday, 29'th Oct 2024
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Hims & Hers Health, Inc. (HIMS) Earnings Expected to Grow: Should You Buy?
11:05am, Monday, 28'th Oct 2024
Hims & Hers Health (HIMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Top 3 Stocks Institutions Are Buying Right Now
08:56am, Monday, 28'th Oct 2024
Despite the S&P 500 trading near its all-time high today, some stocks still offer a potential buy opportunity for investors to consider, especially after some institutions have come along to buy and i
Hims & Hers Health, Inc. (HIMS) Exceeds Market Returns: Some Facts to Consider
06:50pm, Thursday, 24'th Oct 2024
In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $21.52, marking a +0.65% move from the previous day.
